Infectious disease
Vir Biotechnology and GlaxoSmithKline dosed the first patient in a new sub-trial of a Phase III study assessing the monoclonal antibody VIR-7831 as a potential treatment of hospitalized adults diagnosed with COVID-19.
A study in Nature Neuroscience shows SARS-CoV-2, the virus responsible for COVID-19, is capable of crossing the blood-brain barrier, likely contributing to symptoms of brain fog and other cognitive effects reported by people infected with the virus.
It seems like history is repeating itself from just a week ago. Yesterday, the U.S. Food and Drug Administration (FDA)’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommended the agency grant Moderna’s COVID-19 vaccine emergency use authorization (EUA).
Shares of Mesoblast Limited are down more than 30% in premarket trading following the company’s disappointing announcement late Thursday regarding its stem-cell therapy trial in ventilator-dependent patients with COVID-19 patients who have moderate to severe acute respiratory distress syndrome.
As we eagerly look ahead to 2021, BioSpace spoke to four biotechs hoping to seize this opportunity in the first wave of COVID-19 vaccines and therapies – or make an impact in the second.
Despite some setbacks, the company anticipates its vaccine could be available for use in the United Kingdom within the next several weeks.
As Pfizer-BioNTech and the U.S. government begin the historic rollout of COVID-19 vaccine distribution around the U.S. and the world, there have been a few glitches. This isn’t unexpected.
A critical vote is set to take place today amongst those on a U.S. Food and Drug Administration advisory panel in regard to the COVID-19 vaccine from Moderna.
With the first wave of vaccines gaining regulatory approval, nascent biotech companies are looking toward the future, exploring new technologies to make vaccines more effective for more people.
The U.S. Food and Drug Administration has authorized the first non-prescription, over-the-counter, at-home antigen test that can be used to identify infection with SARS-CoV-2, the virus responsible for COVID-19, in people two years of age or older.
PRESS RELEASES